Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioQ Pharma has expanded its license and supply agreement with Sandoz, a division of Novartis, under which Sandoz now has the right to exclusively market an additional ready‐to‐use BioQ Pharma infusion pharmaceutical in the US.
Subscribe to our email newsletter
Under the agreement, BioQ Pharma is responsible for developing and supplying the unit-dose infusion pharmaceutical, and Sandoz is responsible for obtaining regulatory approval, marketing and commercializing the product.
BioQ Pharma president and CEO Josh Kriesel said: "We are pleased to grow our relationship with Sandoz, a leader in the pharmaceutical industry, with the addition of a third infusion product to our previously announced agreement.
"We believe that the presentation of this infusion pharmaceutical, AS-2, may provide important benefits for patients requiring sedation. Additionally, we believe that BioQ Pharma’s ready-to-use infusion system adds value by helping to lower the total cost of drug delivery."
BioQ Pharma Incorporated is a privately held specialty pharmaceutical company focused on developing and commercializing ready-to-use infusible pharmaceuticals. The Company’s infusion platform is intended to address some of the most pressing unmet needs in drug infusion today: cost, medication error, sterility, efficiency, and patient quality of life.
BioQ Pharma’s vision is to set a new standard of care in the presentation and administration of infusible pharmaceuticals via the Company’s proprietary unit-dose infusion systems that can be deployed quickly and conveniently at the point of care with one touch